

PLEASE AMEND THE SPECIFICATION AS FOLLOWS:

In the Specification:

Please insert the following as the first sentence of the application after "CROSS-REFERENCE TO RELATED APPLICATIONS":

A1 /-This application claims the benefits of U. S. Provisional Application Serial Number 60/082,643."--

In the Claims:

Amend Claim 23 with the clean version provided immediately below to read as follows:

23. (Amended) A method of making an human autoantigenic fragment from an human autoantigen comprising the steps of
(a) isolating cells containing at least one human autoantigen, and
(b) contacting the cells with a lymphocyte granule enzyme to produce a mixture containing at least one human autoantigenic fragment.

A2 Amend Claim 24 with the clean version provided immediately below to read as follows:

24. (Amended) The method of claim 23 further comprising the step of
(c) isolating said at least one human autoantigenic fragment.

Amend Claim 25 with the clean version provided immediately below to read as follows:

25. (Amended) The method of claim 23 wherein step (a) further comprises purifying at least one human autoantigen from the cells and step (b) comprises contacting said purified human autoantigen[s] with granzyme B.

Amend Claim 26 with the clean version provided immediately below to read as follows:

26. (Amended) The method of claim 25 wherein in step (a) the at least one autoantigen is at least one of human DNA-PK_{cs}, human PARP and human NuMA, and step (b) comprises contacting said at least one human autoantigen with granzyme B.

Amend Claim 27 with the clean version provided immediately below to read as follows:

27. (Amended) The method of claim 23 wherein said lymphocyte granule enzyme is isolated from the granules of at least one lymphocyte selected from the group consisting of cytotoxic T lymphocytes (CTL), natural killer cells (NK), lymphokine activated killer cells (LAK) and cells of the YT cell line.

Please add the following new claim.

30. The method of claim 23 wherein step (b) further comprises contacting the cells with a caspase inhibitor.

REMARKS

Restriction Requirement

Applicant acknowledges the Examiner's decision to make the Requirement for Restriction final in view of Applicant's traverse. Applicant understands that Claims 23-27 are pending and Claims 1-22, 28 and 29 are withdrawn from consideration at this time.

Amendment of the Claims

Claims 24, 25 and 27 are amended to properly state their dependence on Claim 23.

Applicant has taken the opportunity of this Amendment to make some clarifying amendments in the claims. Specifically, Applicant's presently claimed method, as described in the specification, is directed to the field of autoimmunity in humans. In particular, the method